top of page
​
WhartSep is fitting hospital’s constraints, providing “off-the-shelf” cells that can be stored frozen for years prior to being injected to patients.
The product is classified as an ATMP (Advanced-Therapy Medicinal Product) by the EMA (European Medicines Agency).
Today, treatments in development, such as mAbs/NCEs are facing similar limitations: 1 drug, 1 mode of action, for multiple combined effects pathology.
On the contrary, WhartSep’s biological features show unique advantages, tackling the complexity of severe pneumonia, acting on various aspects of the pathology and adapting to the patient’s needs.
​
WhartSep is in phase Ib entry in severe pneumonia
WORSENING OF SEPSIS LEADS TO HIGH MORTALITY AND TO HIGH MORBIDITY RATES
Major unmet medical need
A costly disease with limited solutions
bottom of page